Cosentyx manufacturer?

Who is the manufacturer of Cosentyx?

Novartis is the manufacturer of Cosentyx (secukinumab), a medication used to treat psoriasis, psoriatic arthritis, and plaque psoriasis in adults.

History of Development

Cosentyx was developed by Novartis Pharmaceuticals Corporation [1]. It was approved by the U.S. Food and Drug Administration (FDA) in March 2015 for the treatment of moderate-to-severe plaque psoriasis.

Marketing and Sales

Novartis has been responsible for the marketing and sales of Cosentyx worldwide. The company has made significant investments in promoting the drug, including launching a dedicated website and providing educational materials for healthcare professionals.

Patent Exclusivity

According to the patents listed on DrugPatentWatch.com [2], Novartis's patent for Cosentyx is set to expire in 2034 for the treatment of psoriasis and psoriatic arthritis. However, this timeline may be subject to change due to potential patent challenges or modifications.

References

[1] Novartis Pharmaceuticals Corporation. (2023). Secukinumab. Retrieved from https://www.novartis.com/products/secukinumab

[2] DrugPatentWatch.com. (2023). Secukinumab (Cosentyx) Patent Expiration and Generic Entry Dates. Retrieved from https://www.drugpatentwatch.com/patent/US20130170088A1

Note: The information provided is accurate as of the date of knowledge cutoff (December 2023) and may change over time.